[HTML][HTML] SARS-CoV-2 variant biology: immune escape, transmission and fitness
AM Carabelli, TP Peacock, LG Thorne… - Nature Reviews …, 2023 - nature.com
In late 2020, after circulating for almost a year in the human population, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …
The immunology and immunopathology of COVID-19
Considerable research effort has been made worldwide to decipher the immune response
triggered upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections …
triggered upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections …
[HTML][HTML] Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum
A Tuekprakhon, R Nutalai, A Dijokaite-Guraliuc… - Cell, 2022 - cell.com
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …
[HTML][HTML] SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …
and are especially important in high-risk individuals where vaccination is not an option …
The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant
D Tian, Y Sun, H Xu, Q Ye - Journal of medical virology, 2022 - Wiley Online Library
Recently, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron
variant (B. 1.1. 529) was first identified in Botswana in November 2021. It was first reported …
variant (B. 1.1. 529) was first identified in Botswana in November 2021. It was first reported …
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double …
H Montgomery, FDR Hobbs, F Padilla… - The Lancet …, 2022 - thelancet.com
Background Early intramuscular administration of SARS-CoV-2-neutralising monoclonal
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …
[HTML][HTML] FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-
converting enzyme 2 (ACE2), could represent a new chemoprophylactic approach for …
converting enzyme 2 (ACE2), could represent a new chemoprophylactic approach for …
SARS-CoV-2 evolution in the Omicron era
C Roemer, DJ Sheward, R Hisner, F Gueli… - Nature …, 2023 - nature.com
Abstract Since SARS-CoV-2 BA. 5 (Omicron) emerged and spread in 2022, Omicron
lineages have markedly diversified. Here we review the evolutionary trajectories and …
lineages have markedly diversified. Here we review the evolutionary trajectories and …
[HTML][HTML] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B. 1.1.
529 was announced, containing far more mutations in Spike (S) than previously reported …
529 was announced, containing far more mutations in Spike (S) than previously reported …
[HTML][HTML] Infectious disease in an era of global change
The twenty-first century has witnessed a wave of severe infectious disease outbreaks, not
least the COVID-19 pandemic, which has had a devastating impact on lives and livelihoods …
least the COVID-19 pandemic, which has had a devastating impact on lives and livelihoods …